GlassScriptPhysician profile
Joseph A Richards
NPI 1477835064
$1,814.99
in general payments reported to CMS, 2019-2025
14 companies · $986 in 2025
The $986 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.08 · 2023: $244 · 2024: $568 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $345.76 | 2024-2025 | |
| Biomerieux INC | $173.01 | 2025 | |
| Edwards Lifesciences Corporation | $148.37 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $137.71 | 2025 | Rejoyn |
| Teva Pharmaceuticals USA, INC. | $132.08 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $124.99 | 2025 | |
| Amgen INC. | $124.46 | 2025 | Evenity |
| Lilly USA, LLC | $122.55 | 2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $121.87 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.86 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.02 | 2025 | Xifaxan |
| Csl Behring | $104.99 | 2024-2025 | Kcentra, Haegarda |
| Viatris Specialty LLC | $22.24 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.